For the year ending 2025-12-31, CPRX had $191,618K increase in cash & cash equivalents over the period. $208,612K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 214,326 |
| Depreciation | 375 |
| Stock-based compensation | 24,778 |
| Amortization of intangible assets | 37,498 |
| Deferred taxes | 6,849 |
| Accretion of discount | 350 |
| Reduction in the carrying amount of right-of-use asset | 295 |
| Acquired inventory samples expensed from asset acquisition | 0 |
| Acquired in-process research and development | 0 |
| Change in fair value of equity securities | 972 |
| Inventory reserve and write-offs | 464 |
| Accounts receivable, net | 61,001 |
| Inventory, net | 18,089 |
| Prepaid expenses and other current assets | 177 |
| Accounts payable | -5,391 |
| Accrued expenses and other liabilities | 24,164 |
| Operating lease liability | -401 |
| Net cash provided by (used in) operating activities | 208,670 |
| Purchases of property and equipment | 58 |
| Payments in connection with asset acquisitions | 0 |
| Acquisition of in-process research and development | 0 |
| Purchase of equity securities | 0 |
| Net cash provided by (used in) investing activities | -58 |
| Payment of employee withholding tax related to stock-based compensation | 1,773 |
| Proceeds from exercise of stock options | 14,669 |
| Repurchase of common stock | 25,300 |
| Payment of liabilities arising from asset acquisition | 4,590 |
| Proceeds from issuance of common stock | 0 |
| Payment of fees in connection with issuance of common stock | 0 |
| Net cash provided by (used in) financing activities | -16,994 |
| Net increase (decrease) in cash and cash equivalents | 191,618 |
| Cash and cash equivalents beginning of period | 517,553 |
| Cash and cash equivalents end of period | 709,171 |
CATALYST PHARMACEUTICALS, INC. (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX)